Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer
Authors
Keywords
Breast cancer, Cancers and neoplasms, Endocrine therapy, Thymidines, Cancer treatment, Chemotherapeutic agents, BT474 cells, Apoptosis
Journal
PLoS One
Volume 16, Issue 6, Pages e0252822
Publisher
Public Library of Science (PLoS)
Online
2021-06-09
DOI
10.1371/journal.pone.0252822
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
- (2019) et al. JAMA Oncology
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of pharmacogenetics in capecitabine efficacy and toxicity
- (2016) S.W. Lam et al. CANCER TREATMENT REVIEWS
- Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial
- (2016) Tsutomu Takashima et al. LANCET ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Roles for miRNAs in endocrine resistance in breast cancer
- (2015) Penn Muluhngwi et al. ENDOCRINE-RELATED CANCER
- Quantitative assessment of appearance changes and related distress in cancer patients
- (2013) Keiko Nozawa et al. PSYCHO-ONCOLOGY
- Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)
- (2013) JICHUN ZHOU et al. Oncology Letters
- Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues
- (2012) Takeshi Hirota et al. LUNG CANCER
- Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer
- (2011) Tokiko Ito et al. BREAST CANCER RESEARCH AND TREATMENT
- Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer
- (2011) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line chemotherapy with or without biologic agents for metastatic breast cancer
- (2010) Claudia Andreetta et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer
- (2009) Junichi Kurebayashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Contemporary issues and the potential uses of capecitabine in metastatic breast cancer
- (2009) Peter Barrett-Lee et al. CANCER TREATMENT REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started